University of Utah scientists are studying Lanmaoa asiatica, a mushroom that induces remarkably specific hallucinations, potentially revealing a new psychoactive compound and offering insights into psychedelic therapies.

Unique Hallucinogenic Effects

Researchers at the University of Utah are delving into the properties of *Lanmaoa asiatica*, found in China and other parts of Asia. Unlike typical psychedelic experiences, this mushroom reportedly causes users to perceive ‘whimsical little fairies and elves’ – tiny, brightly dressed figures engaging in playful activities.

Vivid and Interactive Visions

Colin Domnauer, a researcher at the Natural History Museum of Utah, describes these visions as incredibly vivid and interactive, with the figures appearing to climb furniture and ‘tease people.’ This is particularly intriguing because the mushroom doesn’t contain psilocybin, the common hallucinogenic compound found in ‘magic mushrooms.’

Identifying the Psychoactive Compound

The research team, one of only two labs globally studying *Lanmaoa asiatica*, is employing genome sequencing to identify the compound responsible for these unique effects. Initial investigations have ruled out known hallucinogens, leading researchers to believe they are on the verge of discovering a novel psychedelic.

Local Consumption and Safety

Domnauer experienced the mushroom’s effects firsthand during a trip to China, where it’s commonly sold in markets and consumed in hot-pot dishes. Locals advise waiting 15 minutes after cooking the mushroom to avoid the hallucinatory effects, highlighting its known side effect. Despite numerous cases of consumption in the Yunnan Province, there have been no reported deaths or organ damage, suggesting a relatively safe profile.

Relevance to Psychedelic Therapies

The investigation into *Lanmaoa asiatica* gains added relevance in light of growing interest in psychedelic therapies. Former President Donald Trump issued an executive order aimed at increasing access to psychedelic drugs for treating mental health conditions, allocating $50 million in federal funds and directing the FDA to expedite the review process for substances like psilocybin and ibogaine.

Historical Context

Initial reports of the mushroom’s effects date back to 1934 from Papua New Guinea, where missionaries observed unusual behavior after locals consumed it. Early investigations failed to identify any active compounds, leading to the dismissal of the reports. Subsequent reports from southern China confirmed similar experiences, prompting renewed scientific interest.

Domnauer emphasizes the importance of Bryn Dentinger, the lab director, for supporting this unconventional research, recognizing the risk involved in pursuing a phenomenon previously dismissed by the scientific community.